Selective serotonin reuptake inhibitor prescribing before, during and after pregnancy:a population-based study in six European regions by Charlton, R. A. et al.
        
Citation for published version:
Charlton, RA, Jordan, S, Pierini, A, Garne, E, Neville, AJ, Hansen, AV, Gini, R, Thayer, D, Tingay, K, Puccini, A,
Bos, HJ, Nybo Andersen, AM, Sinclair, M, Dolk, H & De Jong-Van Den Berg, LTW 2015, 'Selective serotonin
reuptake inhibitor prescribing before, during and after pregnancy: a population-based study in six European
regions', BJOG : An International Journal Of Obstetrics & Gynaecology, vol. 122, no. 7, pp. 1010-1020.
https://doi.org/10.1111/1471-0528.13143
DOI:
10.1111/1471-0528.13143
Publication date:
2015
Document Version
Peer reviewed version
Link to publication
University of Bath
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 13. May. 2019
1 
 
Title: SSRI prescribing before, during and after pregnancy: a population-based study in 6 
European regions  
 
R A Charlton, S Jordan, A Pierini, E Garne, A J Neville, A V Hansen, R Gini, D Thayer, K Tingay, 
A Puccini, H J Bos, A M Nybo Andersen, M Sinclair, H Dolk, L T W de Jong-van den Berg 
 
 
 
R A Charlton, Research Fellow, Department of Pharmacy and Pharmacology, University of Bath, 
Bath, BA2 7AY, United Kingdom  
 
S Jordan, Reader, Department of Nursing, College of Human and Health Sciences, Swansea 
University, Swansea,  SA2 8PP, Wales, United Kingdom 
 
A Pierini, Senior researcher, Institute of Clinical Physiology - National Research Council (IFC-CNR), 
Pisa, Italy  
 
E Garne, MD, Paediatric Department, Hospital Lillebaelt, Kolding, Denmark 
 
A J Neville, Coordinator responsible for pharmacovigilance, IMER (Emilia Romagna Registry of Birth 
Defects), Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy 
 
A V Hansen, Research assistant, Paediatric Department, Hospital Lillebaelt, Kolding, Denmark  
 
R Gini, Senior researcher, Agenzia regionale di sanità della Toscana, Via Pietro Dazzi 1, 50141 
Florence, Italy 
 
D Thayer, Research analyst, Centre for Health Information, Research and Evaluation, Swansea 
University, Swansea, SA2 8PP, Wales, United Kingdom 
 
K Tingay, Research analyst, Centre for Health Information, Research and Evaluation, Swansea 
University, Swansea, SA2 8PP, Wales, United Kingdom 
 
A Puccini, Statistician, Drug Policy Service, Emilia Romagna Region Health Authority, Bologna, Italy 
 
H J Bos, IADB.nl Data Manager, Pharmacoepidemiology and Pharmacoeconomics unit, Department 
of Pharmacy, University of Groningen, The Netherlands. 
 
A M Nybo Andersen, Professor of Social Epidemiology, Department of Public Health, University of 
Copenhagen, Denmark 
 
M Sinclair, Professor of Midwifery Research, Maternal, Fetal and Infant Research Centre, University 
of Ulster, Northern Ireland 
 
H Dolk, Professor of Epidemiology and Health Services Research, Institute of Nursing, University of 
Ulster, Northern Ireland 
 
L T W de Jong-van den Berg, Professor Emeritus of Pharmacoepidemiology, Pharmacoepidemiology 
and Pharmacoeconomics unit, Department of Pharmacy, University of Groningen, The Netherlands. 
 
 
2 
 
Corresponding author details -  
Dr Rachel A Charlton 
Department of Pharmacy and Pharmacology,  
University of Bath,  
Bath,  
BA2 7AY  
United Kingdom  
r.a.charlton@bath.ac.uk  
 
Running title 
SSRI prescribing in pregnancy: a study in 6 European databases 
 
 
Word count 
Full text    =   3,251 words 
 
Tables 2 
Figures    4  
 Online supplement figures 1 
3 
 
Summary (250 words) 
 
Objectives  To explore prescribing patterns of selective serotonin reuptake inhibitors (SSRIs) 
before, during and after pregnancy in six European population-based databases. 
 
Design  Descriptive drug utilisation study.  
 
Setting  Six electronic healthcare databases in Denmark, the Netherlands, Italy (Emilia 
Romagna/Tuscany), Wales and the rest of the United Kingdom (UK). 
 
Population  All women with a pregnancy ending in a live or stillbirth starting and ending 
between 2004 and 2010. 
 
Methods A common protocol was implemented across databases to identify SSRI 
prescriptions issued (UK) or dispensed (non-UK) in the year before, during or year following 
pregnancy.  
 
Main outcome measures  The percentage of deliveries where the woman received an SSRI 
prescription in the year before, during or year following pregnancy. We also compared the 
choice of SSRIs and changes in prescribing over the study period. 
 
Results  721,632 women and 862,943 deliveries were identified. In the year preceding 
pregnancy, the prevalence of SSRI prescribing was highest in Wales (9.6% CI959.4-9.8%) and 
lowest in Emilia Romagna (3.3% CI953.2-3.4%). During pregnancy, SSRI prescribing had 
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dropped to between 1.2% (CI951.1-1.3) in Emilia Romagna and 4.5% (CI954.3-4.6) in Wales. 
The higher UK pre-pregnancy prescribing rates resulted in higher first trimester exposures. 
After pregnancy, SSRI prescribing increased most rapidly in the UK. Paroxetine was more 
commonly prescribed in the Netherlands and Italian regions than in Denmark and the UK.  
 
Conclusions  The higher SSRI prescribing rates in the UK, compared with other European 
regions, raise questions about differences in the prevalence and severity of depression and 
its management in pregnancy across Europe. 
 
 
Key words 
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Introduction  
Depression is common among women of child bearing age[1] and the prevalence of 
depression affecting women during pregnancy has been reported to range from 6% to 
13%.[2, 3] Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed 
class of antidepressant[4] and studies evaluating patterns of prescribing have shown that 
between 2.8%[5] and 10.2%[6] of women receive an SSRI prescription at some point during 
pregnancy. The proportion of pregnant women prescribed or dispensed an SSRI varies by 
geographical location, study setting and calendar year, with an increase in prescribing over 
time observed between 1995 and 2008.[6-8]  
 
The effect of in utero SSRI exposure and exposure via breast milk is incompletely 
understood; some, not all, observational studies indicate that exposure during pregnancy is 
associated with a number of adverse perinatal and fetal outcomes.[9-16] Untreated 
depression and treatment discontinuation, however, are not without potential risks to both 
the woman and the developing fetus.[15, 17] Complex decisions therefore need to be made, 
by women and healthcare professionals, balancing the potential risks of fetal exposure with 
the risks of no treatment or treatment discontinuation. As many pregnancies are 
unplanned,[18] it is important women of childbearing age receive appropriate information 
when SSRI treatment is commenced. 
 
The extent of SSRI prescribing during pregnancy has been reported for some geographical 
regions, but for others it is still unknown. To our knowledge, this is the first study including 
pre- and post-pregnancy prescribing in multiple areas of Europe. An understanding of 
variations in prescribing patterns can inform the interpretation of potential safety signals 
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and identify areas requiring further research. This study aims to describe the extent and 
nature of SSRI prescribing to women before, during and after pregnancy in six European 
population-based healthcare databases between 2004 and 2010. This study forms part of 
EUROmediCAT,[19] a Seventh Framework Programme study funded by the European Union 
that aims to make more systematic use of electronic healthcare databases in combination 
with EUROCAT[20] congenital anomalies data.  
 
Methods 
Setting 
Six population-based electronic healthcare databases, that captured pregnancies and 
prescription data, contributed to the study; two in Italy (Tuscany[21] and Emilia Romagna[22]), 
two in the United Kingdom (the Secure Anonymised Information Linkage [SAIL] Databank in 
Wales[23, 24] and the UK-wide Clinical Practice Research Datalink [CPRD][25] with data from 
Wales excluded), one in Denmark[26-28] and one in the Netherlands[29] (Table 1). A more 
detailed description of the databases can be found elsewhere.[30] Where multiple databases 
were linked, such as in Denmark where the information on all pregnancies from the Danish 
National Patient Register was linked to the Danish National Prescription Registry, for the 
remainder of this paper these linked databases will be referred to as a single database. 
Ethical and data access approvals were obtained for each database from the relevant 
governance infrastructures. 
 
Data extraction 
All databases followed a common protocol. Within each database all pregnancies starting 
and ending between 1 January 2004 and 31 December 2010 (except for Denmark where the 
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final date was 31 December 2009) were identified and the best estimate of the start of 
pregnancy was calculated. Pregnancies were eligible for the study if they ended in a delivery 
(live birth or stillbirth) and the woman had been present in the database, capturing 
prescription data, during the year before pregnancy, throughout pregnancy and the year 
following pregnancy. All SSRI prescriptions recorded in the databases during the time period 
of interest were identified. In the UK databases this included all SSRI prescriptions issued 
whilst in the other databases it was only SSRI prescriptions actually dispensed. SSRIs were 
defined as products with an Anatomical Therapeutic Chemical (ATC) code starting N06AB 
and included fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine and escitalopram.  
 
Analyses 
The percentage of women receiving (issued/dispensed) an SSRI prescription, in each of the 
databases, was calculated for the year leading up to pregnancy, during pregnancy and the 
year following pregnancy. Percentages were calculated by dividing the number of deliveries 
in which the woman received an SSRI prescription, during the period of interest, by the total 
number of deliveries. Prescribing patterns were described for each pregnancy trimester and 
for 3-month time periods during the years before and after pregnancy. The choice of 
specific SSRI, co-prescribing of antipsychotics, anxiolytics and hypnotics, and changes in 
prescribing over calendar time were described and compared. 
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Results 
In the six databases 721,632 eligible women with 862,943 deliveries were identified. The 
mean maternal age at the start of pregnancy ranged from 27.7 years [SD1 6.1] in Wales to 
32.3 years [SD 4.9] in Italy (Emilia Romagna) and was significantly lower in Wales than other 
regions, including the rest of the UK (GPRD) (p<0.001). Of all the deliveries, 5.4% (CI95 5.3-
5.4%) of women received a prescription for an SSRI during the year before pregnancy, 
ranging from 3.3% (CI95 3.2-3.4%) in Emilia Romagna to 9.6% (CI95 9.4-9.8%) in Wales. During 
pregnancy the percentage of women receiving an SSRI prescription fell to 2.3% (CI95 2.2-
2.3%) ranging from 1.2% (CI95 1.1-1.3%) in Emilia Romagna to 4.5% (CI95 4.3-4.6%) in Wales 
(Table 2).  
 
SSRI prescribing during the year before and the year after pregnancy was considerably 
higher in both of the UK databases compared to the Danish, Dutch and Italian databases 
(Table 2). The higher pre-pregnancy rates in the UK resulted in higher first trimester 
exposures. During the second and third trimesters however, where SSRI prescribing in all 
databases was at its lowest, the UK figures were in line with those of Denmark and the 
Netherlands (Figure 1). After pregnancy, SSRI prescribing increased more rapidly in the UK 
databases than others and the prevalence of use was considerably higher than pre-
pregnancy. Outside the UK, by six months post-pregnancy the prevalence of SSRI prescribing 
had returned to pre-pregnancy levels (Figure 1). 
 
Figure 2 shows the starting and stopping prescribing scenarios for women who received an 
SSRI prescription during the year before pregnancy. Approximately 27% in the Dutch and 
                                                          
1 SD = standard deviation 
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Danish databases continued receiving prescriptions throughout pregnancy and during the 
year following pregnancy, compared with 10-12% in the UK databases and 4-9% in the 
Italian databases (Figure 2). Approximately 40% of women in the Dutch, Danish and UK 
databases stopped SSRI treatment before pregnancy and did not receive an SSRI 
prescription during pregnancy or in the year following delivery; in Italy this percentage was 
higher at 56% in Tuscany and 67% in Emilia Romagna (Figure 2). In the UK databases a 
further 25% discontinued before pregnancy but restarted during the year after pregnancy; 
outside the UK this scenario ranged from 10.8% to 14.6% of women. Women who 
discontinued SSRI use before pregnancy were quicker to restart following delivery in the UK 
and the Netherlands than in Italy and Denmark, with around 45% and 30% of the restarters 
doing so within three months of delivery respectively (data not shown). Overall, 0.5% (CI95 
0.5-0.6) of women received their first SSRI prescription during pregnancy, having not 
received a prescription during the year before pregnancy, ranging from 0.3% (CI95 0.2-0.4) in 
the Netherlands to 1.0% (CI95 0.9-1.1) in Wales (data not shown). 
Between 2004 and 2009 a steady increase was observed in the percentage of deliveries 
where the woman received a prescription for an SSRI during any of the pregnancy trimesters 
in Denmark, whilst smaller increases were observed in the UK databases (Figure 3). 
Fluoxetine and citalopram were the SSRIs of choice during pregnancy in Denmark and the 
UK databases, whereas in Italy and the Netherlands paroxetine was more popular (Figure 4). 
There was a steady increase in the use of citalopram and sertraline in the UK and Denmark 
during the study period and a slight decline in paroxetine (data not shown). All other 
prescribing remained relatively constant over time.  
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Levels of co-prescribing of products that act on the central nervous system were found to be 
higher in the Dutch database than those in the UK and Denmark, particularly for anxiolytics 
(Online supplement Figure S1). In the Danish and UK databases levels of co-prescribing of 
anxiolytics and hypnotics/sedatives were similar pre- and post-pregnancy (between 4% and 
6% of those receiving a prescription for an SSRI) with a small decline during the three 
pregnancy trimesters. Data on co-prescribing of antipsychotics in Italy is likely to have 
underestimated actual use, as some of the products available are not reimbursed by the 
Italian health service and therefore escape recording. No data was available on co-
prescribing of anxiolytics and hypnotics/sedatives in Italy as those drugs are not reimbursed 
by the Italian health service.  
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Discussion 
Main findings 
Across Europe, marked differences appear to exist in the extent of SSRI prescribing to 
women before, during and after pregnancy, although these differences may be magnified by 
the UK databases recording prescriptions issued and the non-UK databases recording 
prescriptions dispensed. The prescribing of SSRIs was considerably higher in both UK 
databases than in Danish, Dutch and Italian databases. In all databases, SSRI prescribing was 
at its lowest during the second and third trimesters of pregnancy. At least 40% of those with 
a prescription during the year preceding pregnancy discontinued before pregnancy and did 
not restart during the year following delivery. Of those who received a prescription in the 
year before pregnancy, the Danish and Dutch databases had the highest percentage of 
women continuing SSRI treatment throughout pregnancy and following delivery, and the 
Italian databases had the lowest. Differences were observed in terms of the most commonly 
prescribed SSRIs during pregnancy.  
 
Strengths and limitations  
This study captured over 850,000 pregnancies in six different areas of Europe. SSRI 
prescribing was recorded independently by the prescriber or pharmacist, so ascertainment 
was not reliant on maternal involvement which can result in potential recall and selection 
biases.[31, 32] The shared data extraction protocol ensured the study results were as 
comparable as possible across databases. However, differences did exist between 
healthcare systems and the type of data available for research. Data in the UK databases 
were based on prescriptions issued whereas in Denmark, the Netherlands and Italy, data 
were based on prescriptions dispensed by a pharmacist. Some women who receive 
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prescriptions for antidepressants choose not to redeem them from the pharmacist[33] and 
this may explain some, but not all, of the difference between the UK databases and other 
regions. The rate of prescription redemption is difficult to quantify and likely to vary by 
region, study population, type of drug, and even a life event such as pregnancy. A study 
carried out in the UK in the late 1980s, looking at prescription redemption for all 
medicines,[34] found young women to be particularly poor redeemers with 27.6% of women 
aged 16-29 years not redeeming their prescriptions; it is unclear whether this is still the case 
and whether it applies specifically to SSRIs. Studies of antidepressant prescription 
redemption have reported rates ranging from 78.6% in the United States[35] to 95.8% in the 
Netherlands where 23.7% filled only a single prescription.[33] However, even if we 
conservatively assume that 25% of prescriptions in the UK are not redeemed, the 
differences observed in our study are much larger than this. 
 
In the UK, the GP is the main source of SSRI prescribing whilst in other European countries a 
hospital specialist may be more likely to prescribe directly to the patient. In Denmark and 
the Netherlands all SSRI prescriptions were captured, with the exception of those issued 
during a hospital stay. Although prescriptions issued during a hospital stay, prescriptions 
initiated by a specialist in a hospital outpatient department and private prescriptions were 
rarely recorded in the UK databases, the numbers were likely to be small. In Italy, 
prescriptions issued privately or by a specialist that were dispensed at a hospital pharmacy 
were not captured; based on data from Emilia Romagna for 2010-2011, when this data 
became included in the database, hospital prescriptions are thought to represent 
approximately 10% of all SSRI prescribing (A Puccini - personal correspondence).  
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In three databases it was necessary to estimate, for some pregnancies, the duration of 
pregnancy and the date of the last menstrual period (see Table 1 for details), and this may 
have resulted in some exposure status misclassification. Our figures are based on women 
who received a prescription for an SSRI during eleven 3-month time periods, and we do not 
know whether they actually took the product or took it as instructed. In addition, this study 
did not account for prescriptions issued during one 3-month time period which could have 
continued to be consumed during the following 3-month time period and this will have 
resulted in an underestimation of exposure during some time periods.  
 
This study did not examine the prevalence of depression or the use of other 
antidepressants. The findings therefore do not reflect the full extent to which women are 
exposed to antidepressants before, during and after pregnancy. It is possible that the higher 
levels of SSRI prescribing in the UK/Wales could in part be explained by SSRIs making up a 
larger percentage of all antidepressant prescribing in the UK than in the other regions, but it 
was not possible to look at this as part of this study. Current UK prescribing guidelines 
however advise that tricyclic antidepressants are safer in pregnancy than other 
antidepressants.[36] This study did not examine the indications for prescribing; SSRIs are 
indicated for a range of conditions in addition to depression and these may vary between 
regions. No data was available on the appropriateness of use or the efficacy of SSRIs used.  
 
Comparison with other studies 
The percentages of women receiving prescriptions for SSRIs during pregnancy in the areas 
captured by this study correspond well with other studies for the UK as a whole,[37] and the 
Netherlands.[8, 38] In Denmark, the steady increase in SSRI prescribing during the study 
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period was in line with the increase in SSRI prescribing reported for the general population 
during a similar study period in Denmark.[39] It is not clear, however, whether this trend has 
continued after 2009. To our knowledge this is the first study to look at the extent of SSRI 
prescribing during pregnancy in an Italian population. Prescribing of SSRIs during pregnancy 
in all European databases was lower than in the United States[6, 7, 40, 41] where studies have 
reported percentages of between 5.6%[40] and 10.2%,[6] depending on the years of study and 
the study setting. The proportions of women receiving prescriptions for SSRIs during the 
first trimester of pregnancy in the UK were similar to those reported for Australia[9] and 
Canada.[42] 
 
Interpretation 
Other than methodological factors, difference in prescribing may reflect differences in the 
prevalence of depression, in the severity of depression, in help seeking behaviour, or 
prescribing behaviour at national and subnational level. Although the two UK databases 
both collected data on prescriptions issued, higher levels of SSRI prescribing to women were 
observed in Wales than in the rest of the UK. This may reflect the higher number of 
antidepressants prescribed per capita in Wales,[43] and the lower socioeconomic status and 
per capita income in Wales[44] may also in part explain the discrepancies in prescribing. 
Regional differences were also observed in Italy with a lower percentage of females 
receiving a prescription for an SSRI in Emilia Romagna than in Tuscany, this however appears 
to be in line with regional SSRI prescribing differences observed for the general 
population.[45]  
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The popularity of paroxetine in Italy and the Netherlands and the absence of a reduction in 
its prescribing over the study period are surprising given the number of studies that have 
demonstrated an increase in the risk of congenital heart defects associated with paroxetine 
exposure during the early stages of pregnancy.[9, 12, 46] In the Netherlands, new guidelines on 
the prescribing of SSRIs during pregnancy were issued in 2012, after the end of our study 
period; these do not specify a preferred SSRI but do recommend that if paroxetine is taken 
during the periconceptional period the dose should not exceed 20mg per day.[47] In Italy an 
official safety note was issued by the Italian Medicine Agency in February 2006[48] and in 
November 2010, at the end of the study period, a recommendation was issued by the 
Agency’s Paediatric Working Group suggesting paroxetine should only be used when strictly 
indicated.[49] UK guidelines recommend that if a woman taking paroxetine is planning a 
pregnancy or has an unplanned pregnancy, she should be advised to stop taking the drug 
and advise that fluoxetine is the SSRI with the lowest known risk during pregnancy,[36] 
concording with fluoxetine being one of the most popular SSRIs in the UK in our study.  The 
steady increase in use of citalopram and sertraline during the study period in Denmark and 
the slight decline in paroxetine corresponds with changes to the prescribing guidelines.[50] 
 
When a woman becomes pregnant the risk-benefit profile of SSRI medication changes and 
this is evident from the reduction in SSRI use observed in all European regions during the 
first trimester of pregnancy, and the further reduction during the second and third 
trimesters. The efficacy of antidepressant treatment in less than severe depression has been 
questioned,[51] suggesting a negative benefit-risk balance except for severe depression. 
Prescribing guidelines in the UK currently recommend that pregnant women with mild 
depression should have their medication withdrawn and replaced by self-help or 
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psychological treatments.[36] Further research should investigate whether women with mild 
depression are being inappropriately prescribed antidepressants during pregnancy, deriving 
no established benefit but exposing the fetus to possible risk.  Equally important however 
for both mother and baby is to ensure that depression does not go untreated, that 
psychological therapies are available where needed, and that any discontinuation of SSRI 
treatment is done in a controlled manner. We were not able to establish whether the high 
rates of discontinuation before and during pregnancy in Europe reflect controlled 
discontinuation for women who are offered alternative treatments or no longer require 
treatment, or represent unmet need and greater levels of depression-related risk among 
pregnant women. 
 
In Denmark and the Netherlands, a much larger proportion of those using SSRIs before 
pregnancy continued to receive prescriptions during and after pregnancy compared with 
the other European regions. This might reflect a more relaxed attitude to SSRI use during 
pregnancy in Denmark and the Netherlands but, given the lower percentage of women 
receiving an SSRI at any time during the study period, it is likely that, in these countries, a 
larger proportion of women receiving SSRIs have a medical condition severe enough to 
warrant continuation. The differences observed in postnatal prescribing and the point at 
which women who had discontinued treatment restarted following delivery may in part be 
related to differences in the rates of breastfeeding. The percentage of mothers 
breastfeeding to any extent at six weeks postpartum has been reported to be approximately 
55%  in the UK as a whole and 40% in Wales,[52] whereas in Italy 49% of mothers are still 
breastfeeding three months after delivery[53] and in Denmark 60% are breastfeeding at four 
months post-delivery.[54]  The impact of UK guidelines recommending case identification for 
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postnatal depression at 4-6 weeks and 3-4 months post pregnancy[36] is uncertain but may 
have contributed to the higher SSRI prescribing rates observed. Postnatal screening for 
depression was not routinely carried out in the Netherlands, Italy or Denmark during the 
study period and following a policy review in 2011 screening for postnatal depression is no 
longer recommended in the UK.[55] 
 
Conclusion 
The considerably higher levels of SSRI prescribing observed in the UK databases compared 
with other European databases raises questions about differences in the prevalence and 
severity of depression and its management in pregnancy across Europe. The variations 
observed in the type and extent of SSRI prescribing indicates an absence of European 
consensus on prescribing to pregnant women and women of childbearing age.  Further work 
is required to understand the reasons for the higher levels of SSRI prescribing observed in 
the UK databases, and the extent to which these reflect medical need and endemic 
prescribing patterns. Further work is required to better understand the potential adverse 
fetal and child outcomes following SSRI exposure and this is the focus of the current 
EUROmediCAT project.[19]  
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Table 1  Overview of databases contributing to the study 
 
Country/Region 
 
Netherlands 
 
Denmark 
 
Italy - 
Emilia Romagna 
 Italy -   
Tuscany 
United Kingdom1 
 
Wales 
 
Involves database 
record linkage 
No 
 
Yes 
 
Yes 
 
Yes 
 
No 
 
Yes2 
 
Coverage 
 
Regional National Regional Regional Approximately 8.5% 
of UK population 
Approximately 40% 
of GP practices  
Population base 500,000  ~5,000,000 4,200,000 3,700,000  ~5,000,0003 1,200,000 
Database for live & 
stillbirth pregnancy 
identification 
IADB.nl 
 
Danish National  
Patient Register 
 
Certificate of Delivery 
Assistance (CeDAP) 
 
Certificate of Delivery 
Assistance (CeDAP) 
Hospital Discharges 
Registry 
General Practice 
Research Database 
 (GPRD)4 
National 
Community Child 
Health Database 
(NCCHD) 
Database for medicine  
use data 
 
IADB.nl 
 
Danish National  
Prescription 
Registry 
Emilia-Romagna 
Prescription Database 
(ERPD) 
Tuscany Prescription 
Database 
General Practice 
Research Database 
The General 
Practice (GP) 
Dataset 
Source for medicine 
use data 
Pharmacy 
dispensing 
Pharmacy 
dispensing 
Pharmacy  
dispensing5 
Pharmacy dispensing  
and Healthcare 
Facilities Dispensing5 
GP practice 
prescribing 
GP practice 
prescribing 
 
Capture GP prescribing 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Capture outpatient 
prescribing 
Yes 
 
Yes 
 
Yes5 
 
Yes5 
 
Yes6 
 
Yes 
 
Capture inpatient 
prescribing 
No 
 
No 
 
No 
 
No 
 
Some 
 
Some 
 
Date of last menstrual 
period recorded 
Estimated 
for all 
Calculated from 
gestational age 
Calculated from 
gestational age 
Calculated from 
gestational age 
Yes for 40% 
Estimated for 60% 
Yes for 80% 
Estimated for 20% 
Smoking status No Yes7 No Yes Yes Some 
Alcohol consumption No No No No Yes Some 
Pre-pregnancy BMI No Yes6 No Yes Yes Some 
A measure of 
socioeconomic status 
Yes 
 
Yes 
 
Yes 
  
Yes 
 
Yes Yes 
 
                                                          
   1  Excluding practices in Wales to avoid duplication of pregnancies in the database contributing data for Wales 
  2  Secure Anonymised Information Linkage (SAIL) Databank 
  3  The size of the population captured by the GPRD has grown steadily over time and was approximately 5.0 million in May 2012 
  4  Now the Clinical Practice Research Datalink (CPRD) 
  5  Only products reimbursed by the Italian National Health Service and excluding those dispensed to outpatients in a hospital pharmacy 
  6  excluding prescriptions initiated by a specialist in a hospital outpatient department but any repeat prescriptions subsequently issued by the GP were captured 
  7  Available for pregnancies that result in a delivery but not those that end in a pregnancy loss 
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Table 2 Percentage of deliveries in the period 2004-2010 where the woman received a prescription for an SSRI in the year before pregnancy, 
during pregnancy or the year following pregnancy. 
 
 
Country/region 
Number of 
eligible 
deliveries in 
entire cohort 
Mean maternal 
age at pregnancy 
start for entire 
cohort 
SSRI prescription during 
the year before 
pregnancy 
any of the pregnancy 
trimesters 
the year following 
pregnancy 
 N          Years    [SD*] (%) (95% CI) (%) (95% CI) (%) (95% CI) 
The Netherlands 13,935 29.4   [4.8] 3.9 (3.6 - 4.2) 2.3 (2.0 - 2.5) 4.3 (4.0 - 4.6) 
Denmark± 320,846 30.0   [4.9] 4.1 (4.0 - 4.1) 2.3 (2.3 - 2.4) 4.1 (4.0 - 4.2) 
Italy – Emilia Romagna 129,220 32.3   [4.9] 3.3 (3.2 - 3.4) 1.2 (1.1 - 1.3) 2.5 (2.4 - 2.6) 
Italy – Tuscany 157,916 31.8   [4.9] 4.4 (4.3 - 4.5) 1.6 (1.5 - 1.7) 3.4 (3.3 - 3.5) 
United Kingdom* 182,920 30.2   [6.1] 8.8 (8.6 - 8.9) 3.7 (3.6 - 3.8) 12.9 (12.7 - 13.0) 
Wales 58,106 27.7   [6.1] 9.6 (9.4 - 9.8) 4.5 (4.3 - 4.6) 15.0 (14.7 - 15.3) 
† Standard deviation 
± 2004-2009 
* Excluding Wales to avoid duplication of pregnancies in the SAIL databank 
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Figures 
 
 
Figure 1 Percentage of all deliveries between 2004 and 2010 where the woman received a prescription for an SSRI during ≥1 of the time 
periods of interest 
 
 
 
* Excluding Wales 
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Figure 2 Starting and stopping scenarios for deliveries where the mother had an SSRI prescription during the year before pregnancy 
 
 
 
* Excluding Wales 
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Figure 3 Percentage of deliveries where the woman had a prescription for an SSRI during 
any of the pregnancy trimesters by calendar year  
 
 
 
 
* Excluding Wales 
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Figure 4 Percentage of all deliveries between 2004 and 2010 where the woman received a 
prescription for the individual SSRI during any of the pregnancy trimesters 
 
  
  
  
      * excluding Wales 
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Figure S1 Percentage of deliveries where the woman received a prescription for an SSRI 
during the time period of interest, that also received a prescription for a) an antipsychotic, 
b) an anxiolytic and c) a hypnotic/sedative during the time period of interest  
 
a) antipsychotic co-prescribing 
  
b) anxiolytic co-prescribing 
  
c) hypnotic/sedative co-prescribing 
  
      * excluding Wales 
